Northwest Therapies Trauma Psilocybin Study Compassionate Use Study

• Status: Not yet recruiting
• Trial end date: 2024-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The on-boarding of unregulatable trauma in the United States has reached 20%, which1/5 of the population. A population of this magnitude, by definition has reached an epidemic classification. The population with chronic illness as stated: PTSD, Chronic Depression, MS, HIV, and SARS-CoV-2- Long Haulers Syndrome. These chronic illness with unregulated trauma create an unstable portion of the population. Psychiatrists have testified before congress that the SSSRI medications are not functional cures and are not working for patients. Psilocybin micro-dosing is proving to shave back the highjacked nervous system, stopping ruminating neurotransmitter. The body has a natural path to stop these thoughts by a neurotransmitter called serotonin This is the most famous neurotransmitter Serotonin, is very similar to the plant medicine family of psilocybin, Serotonin and psilocybin work very similarly with the 5h2A receptor in the human cortex ( the outer cortex of the brain ). Micodosing 1 gram to 1/5 grams of psilocybin helps shave back the highjacked nervous system known as the diagnosis (SSD) Somatic Symptom Disorder. This research is believed accurate by proof on previous studies to reverse back the somatic feelings resulting from the trauma of the individuals who are on boarding chronic diseases of PTSD, Chronic Depression, MS, HIV, and SARS-CoV-2- Long Haulers Syndrome.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: NWTraumatherapies
• Collaborators: Imperial College London; Johns Hopkins University; World Health Organization
• Treatments: Psilocybin

Criteria

Inclusion Criteria:

Psychiatrist, LCPC Therapist, Administrator, On Boarding Plant Medicine Specialist.

Informed Consent

Exclusion Criteria:

Cardiovascular Complication